{"id":22214,"date":"2022-12-29T11:50:54","date_gmt":"2022-12-29T19:50:54","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=22214"},"modified":"2024-07-09T15:28:18","modified_gmt":"2024-07-09T22:28:18","slug":"xospata-gilteritinib","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/","title":{"rendered":"Xospata (gilteritinib)"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">El c\u00e1ncer es uno de los problemas de salud m\u00e1s mortales del mundo. Se presenta en diversas formas, y una de ellas es la leucemia mieloide aguda (LMA). La LMA es un tipo de c\u00e1ncer de la sangre que se origina en la m\u00e9dula \u00f3sea. Si no se trata a tiempo, este tipo de c\u00e1ncer suele empeorar r\u00e1pidamente. La LMA tambi\u00e9n se denomina leucemia no linfoc\u00edtica aguda o leucemia mieloide aguda.&nbsp;<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-a2f3290f9184eb658f42e56738457f7e\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p><span style=\"font-weight: 400;\">La m\u00e9dula \u00f3sea es una parte fundamental del hueso humano, ya que es responsable de la producci\u00f3n de gl\u00f3bulos blancos, gl\u00f3bulos rojos y plaquetas en el sistema circulatorio. Cuando este c\u00e1ncer afecta la m\u00e9dula \u00f3sea, comienza a producir c\u00e9lulas anormales conocidas como blastos.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Seg\u00fan estudios recientes, la leucemia mieloide aguda (LMA) es el tipo m\u00e1s com\u00fan de leucemia que afecta a los adultos. En Estados Unidos, aproximadamente... <\/span><a href=\"https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html\"><span style=\"font-weight: 400;\">20.000 personas<\/span><\/a><span style=\"font-weight: 400;\"> Cada a\u00f1o, m\u00e1s de 100 personas padecen este c\u00e1ncer y, si bien es com\u00fan entre los adultos, tambi\u00e9n afecta a personas m\u00e1s j\u00f3venes.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">C\u00e1nceres como la leucemia mieloide aguda (LMA) pueden ser causados por mutaciones que desactivan genes supresores de tumores o activan oncogenes. Por ejemplo, en las c\u00e9lulas de LMA pueden ocurrir cambios en genes como c-KIT, FLT3 y RAS. Cambios como estos pueden provocar que las c\u00e9lulas de la m\u00e9dula \u00f3sea crezcan descontroladamente o dejen de madurar normalmente.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Una de las mejores opciones de tratamiento para la leucemia mieloide aguda (LMA) es Xospata. En este art\u00edculo, analizaremos c\u00f3mo funciona este medicamento, la dosis adecuada y sus efectos secundarios.&nbsp;<\/span><\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#What_Is_Xospata\" >\u00bfQu\u00e9 es Xospata?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#Approval_and_Efficacy\" >Aprobaci\u00f3n y eficacia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#Dosage\" >Dosificaci\u00f3n<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#Side_Effects_of_Xospata\" >Efectos secundarios de Xospata<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#Mild_and_Common_Side_Effects\" >Efectos secundarios leves y comunes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#Serious_Side_Effects\" >Efectos secundarios graves<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/#Cost\" >Costo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Is_Xospata\"><\/span>\u00bfQu\u00e9 es Xospata?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Xospata es un medicamento recetado para el tratamiento de la leucemia mieloide aguda (LMA) con una mutaci\u00f3n espec\u00edfica en adultos, conocida como mutaci\u00f3n de la tirosina quinasa 3 similar a FMS (FLT-3). Esta mutaci\u00f3n provoca que las c\u00e9lulas leuc\u00e9micas crezcan y se desarrollen r\u00e1pidamente, lo que reduce la posibilidad de que se produzcan c\u00e9lulas sangu\u00edneas sanas.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">La mutaci\u00f3n tambi\u00e9n es el tipo de mutaci\u00f3n m\u00e1s com\u00fan en pacientes con LMA. <\/span><a href=\"https:\/\/ashpublications.org\/blood\/article\/100\/7\/2393\/106192\/Studies-of-FLT3-mutations-in-paired-presentation#:~:text=FLT3%20mutations%2C%20either%20internal%20tandem,with%20an%20increased%20relapse%20rate.\"><span style=\"font-weight: 400;\">Una de cada tres personas<\/span><\/a><span style=\"font-weight: 400;\"> con LMA tienen la mutaci\u00f3n FLT-3. La administraci\u00f3n de Xospata se realiza despu\u00e9s de que un paciente tenga <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-adult-patients-who-have-relapsed-or-refractory-acute-myeloid-leukemia-aml\"><span style=\"font-weight: 400;\">ha sido probado<\/span><\/a><span style=\"font-weight: 400;\"> por la presencia del gen mutado y si otras formas de tratamiento no han funcionado.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Xospata es el nombre comercial del medicamento cuyo principio activo es gilteritinib. Gilteritinib forma parte de una subclase de f\u00e1rmacos conocidos como inhibidores de la tirosina quinasa (ITK). Estos inhibidores atacan las c\u00e9lulas cancerosas o anormales. Xospata, en particular, inhibe la enzima tirosina quinasa 3 similar a FMS (FLT-3). El medicamento se presenta en comprimidos de 40 mg que se toman enteros. No triture, rompa ni mastique los comprimidos.&nbsp;&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Approval_and_Efficacy\"><\/span>Aprobaci\u00f3n y eficacia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">La Administraci\u00f3n de Alimentos y Medicamentos (FDA) de los EE. UU. ha <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-adult-patients-who-have-relapsed-or-refractory-acute-myeloid-leukemia-aml\"><span style=\"font-weight: 400;\">aprobado<\/span><\/a><span style=\"font-weight: 400;\"> Xospata desde 2018. Esto en el contexto de numerosos estudios que demostraron que Xospata funciona en el tratamiento de la mutaci\u00f3n FLT-3 de la leucemia mieloide aguda.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">En <\/span><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383\"><span style=\"font-weight: 400;\">uno de estos estudios<\/span><\/a><span style=\"font-weight: 400;\">Se compar\u00f3 el efecto de Xospata con el de otras opciones de tratamiento disponibles para la leucemia mieloide aguda (LMA). El objetivo del estudio fue determinar cu\u00e1l de las opciones de tratamiento ayuda a lograr la remisi\u00f3n completa del c\u00e1ncer.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Al final del estudio, se descubri\u00f3 que el 14,2% de las personas que usaron Xospata lograron la remisi\u00f3n en comparaci\u00f3n con el 10,5% de las personas que usaron otras opciones de tratamiento, como <a href=\"https:\/\/ameripharmaspecialty.com\/es\/oral-chemotherapy-cancer-drugs\/\">quimioterapia<\/a>Los participantes que usaron Xospata tambi\u00e9n mantuvieron la remisi\u00f3n m\u00e1s tiempo y vivieron m\u00e1s que los pacientes que recibieron quimioterapia. La diferencia en la duraci\u00f3n de la remisi\u00f3n fue de 13 meses, mientras que la diferencia en la longevidad fue de 4 meses.&nbsp;<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-42b1b8aaa11ef29c253ce227a9ff4a10\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHable con un especialista sobre la asistencia con los copagos\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dosage\"><\/span>Dosificaci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"290\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata.jpg\" alt=\"Patient taking Xospata\" class=\"wp-image-22215\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata-300x207.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata-86x59.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata-167x115.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata-280x193.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/patient-taking-xospata-370x255.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p><span style=\"font-weight: 400;\">Existen diferentes dosis de Xospata para cada persona. Esto se debe a que existen muchos factores que determinan la dosis exacta, entre ellos, las afecciones m\u00e9dicas subyacentes y la gravedad de la leucemia mieloide aguda (LMA).&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">En la mayor\u00eda de los casos, comenzar\u00e1 con una dosis baja y, bas\u00e1ndose en su tasa de respuesta, el m\u00e9dico ajustar\u00e1 la dosis. El objetivo es comenzar con la dosis m\u00e1s baja que proporcione el mayor efecto deseado.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Si nota alg\u00fan efecto secundario, consulte a su m\u00e9dico de inmediato. Lo m\u00e1s probable es que suspenda la administraci\u00f3n del medicamento y luego reduzca la dosis para ayudarle a evitar efectos secundarios.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">La dosis recomendada de Xospata para el tratamiento de la leucemia mieloide aguda es de 120 mg. Puede reducirse a 80 mg si aparecen efectos secundarios. Si olvida una dosis programada y a\u00fan faltan aproximadamente 12 horas para la siguiente, tome el medicamento inmediatamente. Por otro lado, si la siguiente dosis es dentro de las 12 horas, simplemente espere. No tome m\u00e1s de una dosis del medicamento en un plazo de 12 horas.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Tenga en cuenta que este medicamento est\u00e1 dise\u00f1ado para ser un tratamiento a largo plazo. Siempre que el m\u00e9dico determine que es seguro y no experimente efectos secundarios, puede usar Xospata a largo plazo.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Side_Effects_of_Xospata\"><\/span>Efectos secundarios de Xospata<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El uso de Xospata podr\u00eda causar efectos secundarios leves y graves. Tenga en cuenta que los efectos secundarios mencionados a continuaci\u00f3n no representan todas las posibles reacciones asociadas con el medicamento.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Por lo tanto, es importante que hables con tu m\u00e9dico o farmac\u00e9utico para tener una mejor idea de todos los efectos secundarios asociados con el uso de este medicamento.&nbsp;<\/span><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mild_and_Common_Side_Effects\"><\/span>Efectos secundarios leves y comunes<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Algunos de los efectos secundarios comunes que puede experimentar con el uso de Xospata incluyen:<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Fatiga<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Dolor articular y muscular<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Presi\u00f3n arterial baja<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Edema<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Fiebre<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Diarrea<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Llagas o hinchazones en la boca<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Constipaci\u00f3n<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Aumento del nivel de enzimas hep\u00e1ticas<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Erupci\u00f3n cut\u00e1nea<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">dificultad para respirar<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Mareo<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">V\u00f3mitos&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">N\u00e1useas<\/span><\/li>\n<\/ul>\n\n\n\n<p><span style=\"font-weight: 400;\">Estos efectos secundarios se clasifican como leves o comunes porque suelen desaparecer despu\u00e9s de unos d\u00edas o semanas. Sin embargo, si persisten o se agravan, debe consultar con su m\u00e9dico.&nbsp;<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-6ecd5e490506bf2fc7c4454343d8d1be\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tPreg\u00fantele a un especialista sobre los efectos secundarios\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Serious_Side_Effects\"><\/span>Efectos secundarios graves<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><span style=\"font-weight: 400;\">Los siguientes efectos secundarios no son comunes y debe buscar ayuda m\u00e9dica o llamar al 911 inmediatamente despu\u00e9s de comenzar a experimentarlos:<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Pancreatitis<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Hinchaz\u00f3n cerebral, tambi\u00e9n conocida como s\u00edndrome de encefalopat\u00eda posterior reversible<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">ritmo card\u00edaco anormal&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Diferenciaci\u00f3n celular, una condici\u00f3n en la que las c\u00e9lulas cambian y aumentan en n\u00famero. Algunos s\u00edntomas incluyen aumento repentino de peso, fiebre, signos de problemas renales, dificultad para respirar y presi\u00f3n arterial baja. Su m\u00e9dico podr\u00eda interrumpir el tratamiento con Xospata si los signos y s\u00edntomas persisten y reanudarlo cuando estos mejoren.&nbsp;<\/span><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Costo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El costo de Xospata depende de muchos factores. Algunos de ellos incluyen su proveedor de atenci\u00f3n m\u00e9dica, su seguro m\u00e9dico, la farmacia que utiliza y su ubicaci\u00f3n. Dado que el costo var\u00eda seg\u00fan la persona, comun\u00edquese con su farmacia para obtener el precio m\u00e1s actualizado.&nbsp;<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>El c\u00e1ncer es uno de los problemas de salud m\u00e1s mortales del mundo. Se presenta en diversas formas, y una de ellas es la leucemia mieloide aguda (LMA). La LMA es un tipo de c\u00e1ncer de la sangre que se origina en la m\u00e9dula \u00f3sea.<\/p>","protected":false},"author":21,"featured_media":22216,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[13],"tags":[27],"class_list":["post-22214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","tag-dr-abdelaziz-alsamarah"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xospata (Gilteritinib) - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"Xospata is a drug prescribed for the treatment of acute myeloid leukemia. Learn about the dosage, side effects, and efficacy of this drug.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xospata (Gilteritinib) - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"Xospata is a drug prescribed for the treatment of acute myeloid leukemia. Learn about the dosage, side effects, and efficacy of this drug.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-29T19:50:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-09T22:28:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/\"},\"author\":{\"name\":\"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP\",\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#\\\/schema\\\/person\\\/2f73858b25c20aa6bf5b731fd4e593c4\"},\"headline\":\"Xospata (Gilteritinib)\",\"datePublished\":\"2022-12-29T19:50:54+00:00\",\"dateModified\":\"2024-07-09T22:28:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/\"},\"wordCount\":1085,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Xospata-Gilteritinib.jpg\",\"keywords\":[\"Dr. Abdelaziz Alsamarah\"],\"articleSection\":[\"Cancer\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/\",\"name\":\"Xospata (Gilteritinib) - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Xospata-Gilteritinib.jpg\",\"datePublished\":\"2022-12-29T19:50:54+00:00\",\"dateModified\":\"2024-07-09T22:28:18+00:00\",\"description\":\"Xospata is a drug prescribed for the treatment of acute myeloid leukemia. Learn about the dosage, side effects, and efficacy of this drug.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Xospata-Gilteritinib.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Xospata-Gilteritinib.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Doctor diagnosing condition that is treated with Xospata\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/zh\\\/cancer\\\/xospata-gilteritinib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xospata (Gilteritinib)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspe.wpenginepowered.com\\\/#\\\/schema\\\/person\\\/2f73858b25c20aa6bf5b731fd4e593c4\",\"name\":\"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8671a91ecba97f36a7f5e6492c279b433d2a9c2ac61cf480154cdd3c51b5fe3d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8671a91ecba97f36a7f5e6492c279b433d2a9c2ac61cf480154cdd3c51b5fe3d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8671a91ecba97f36a7f5e6492c279b433d2a9c2ac61cf480154cdd3c51b5fe3d?s=96&d=mm&r=g\",\"caption\":\"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP\"},\"description\":\"Dr. Alsamarah received his PharmD degree from the University of Jordan in 2011. In pursuit of higher education, he joined Western University of Health Sciences, Pomona, CA in 2014 and received a masters in pharmaceutical sciences with major in Computer-Aided Drug Design (CADD). He has authored and co-authored several publications in major scientific journals. After graduation, Dr. Alsamarah worked in various pharmacy settings before he found his passion in managing patients on IV infusions. His specialty areas include: Infectious diseases, nutrition support, and monoclonal antibodies. In his free time, he likes boxing, biking, and painting with his three kids.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/abdelaziz\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xospata (gilteritinib) - AmeriPharma\u00ae Atenci\u00f3n especializada","description":"Xospata es un medicamento recetado para el tratamiento de la leucemia mieloide aguda. Inf\u00f3rmese sobre la dosis, los efectos secundarios y la eficacia de este medicamento.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/","og_locale":"es_MX","og_type":"article","og_title":"Xospata (Gilteritinib) - AmeriPharma\u00ae Specialty Care","og_description":"Xospata is a drug prescribed for the treatment of acute myeloid leukemia. Learn about the dosage, side effects, and efficacy of this drug.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/xospata-gilteritinib\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2022-12-29T19:50:54+00:00","article_modified_time":"2024-07-09T22:28:18+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg","type":"image\/jpeg"}],"author":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/"},"author":{"name":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP","@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#\/schema\/person\/2f73858b25c20aa6bf5b731fd4e593c4"},"headline":"Xospata (Gilteritinib)","datePublished":"2022-12-29T19:50:54+00:00","dateModified":"2024-07-09T22:28:18+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/"},"wordCount":1085,"publisher":{"@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg","keywords":["Dr. Abdelaziz Alsamarah"],"articleSection":["Cancer"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/","url":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/","name":"Xospata (gilteritinib) - AmeriPharma\u00ae Atenci\u00f3n especializada","isPartOf":{"@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg","datePublished":"2022-12-29T19:50:54+00:00","dateModified":"2024-07-09T22:28:18+00:00","description":"Xospata es un medicamento recetado para el tratamiento de la leucemia mieloide aguda. Inf\u00f3rmese sobre la dosis, los efectos secundarios y la eficacia de este medicamento.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg","width":1280,"height":853,"caption":"Doctor diagnosing condition that is treated with Xospata"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/zh\/cancer\/xospata-gilteritinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspe.wpenginepowered.com\/es\/"},{"@type":"ListItem","position":2,"name":"Xospata (Gilteritinib)"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#website","url":"https:\/\/ameripharmaspe.wpenginepowered.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspe.wpenginepowered.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspe.wpenginepowered.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspe.wpenginepowered.com\/#\/schema\/person\/2f73858b25c20aa6bf5b731fd4e593c4","name":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8671a91ecba97f36a7f5e6492c279b433d2a9c2ac61cf480154cdd3c51b5fe3d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8671a91ecba97f36a7f5e6492c279b433d2a9c2ac61cf480154cdd3c51b5fe3d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8671a91ecba97f36a7f5e6492c279b433d2a9c2ac61cf480154cdd3c51b5fe3d?s=96&d=mm&r=g","caption":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP"},"description":"El Dr. Alsamarah obtuvo su doctorado en farmacia en la Universidad de Jordania en 2011. Para continuar sus estudios superiores, se incorpor\u00f3 a la Universidad Occidental de Ciencias de la Salud, Pomona, California, en 2014 y obtuvo una maestr\u00eda en ciencias farmac\u00e9uticas con especializaci\u00f3n en Dise\u00f1o de F\u00e1rmacos Asistido por Computadora (CADD). Es autor y coautor de varias publicaciones en importantes revistas cient\u00edficas. Tras graduarse, el Dr. Alsamarah trabaj\u00f3 en diversos entornos farmac\u00e9uticos antes de descubrir su pasi\u00f3n por el manejo de pacientes con infusiones intravenosas. Sus \u00e1reas de especialidad incluyen enfermedades infecciosas, apoyo nutricional y anticuerpos monoclonales. En su tiempo libre, le gusta boxear, montar en bicicleta y pintar con sus tres hijos.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/abdelaziz\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/abdelaziz\/"},"uagb_comment_info":1,"uagb_excerpt":"Cancer is one of the most deadly health issues in the world. It exists in many different forms, and one of these forms is acute myeloid leukemia (AML). AML is a type of blood cancer, and it originates from the bone marrow.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/12\/Xospata-Gilteritinib.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Abdelaziz Alsamarah, PharmD, MSPS, BCSCP","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/abdelaziz\/"},"rttpg_comment":1,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/cancer\/\" rel=\"category tag\">Cancer<\/a>","rttpg_excerpt":"Cancer is one of the most deadly health issues in the world. It exists in many different forms, and one of these forms is acute myeloid leukemia (AML). AML is a type of blood cancer, and it originates from the bone marrow.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=22214"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22214\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/22216"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=22214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=22214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=22214"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}